1.Management of Diabetes in Organ Transplant Patients.
Journal of Korean Diabetes 2014;15(3):134-141
New onset diabetes after transplantation (NODAT) is a common complication after solid-organ transplantation and is associated with increased cardiovascular morbidity, mortality, and graft loss. The risk factors for NODAT include older age, ethnicity, genetic factors,obesity, family history of diabetes, hepatitis C virus infection, and immunosuppressant use (corticosteroids, calcineurin inhibitors, and mTOR inhibitor). Management of NODAT must be considered at the pre-transplantation stage in order to properly screen high-risk patients. Although NODAT management is similar to that of general type 2 diabetes, some specific considerations must be made in NODAT management, including the interactions between anti-diabetes medication and immunosuppressive agents.
Calcineurin
;
Diabetes Mellitus
;
Diagnosis
;
Hepacivirus
;
Humans
;
Immunosuppressive Agents
;
Mortality
;
Organ Transplantation
;
Risk Factors
;
Transplants*
2.Successful Graft Recovery from Thrombotic Acute Kidney Injury in a Kidney Transplant Patient with Antiphospholipid Syndrome.
Younjeong CHOI ; Hyewon LEE ; Yujung YUN ; Youngki LEE ; Eudong HWANG ; Hyeonjoo JEONG ; Beom Seok KIM
The Journal of the Korean Society for Transplantation 2013;27(3):128-131
Antiphospholipid syndrome nephropathy (APSN) is well documented in the literature as the renal involvement of the antiphospholipid syndrome (APS). A review of literature also shows that among antiphospholipid antibodies, lupus anticoagulant (LA) positivity is recognized as the strongest risk factor for APSN. In addition, APSN is also known to be associated with a poor functional outcome in the first posttransplant year. Therefore, it is a general belief that renal transplantation may be life threatening in APS patients. Furthermore, the presence of LA at the time of transplantation is particularly associated with a high rate of allograft APSN and the consequent poor transplantation outcomes. Here, we report the case that thrombotic acute kidney injury due to APSN after kidney transplantation can be successfully treated if anticoagulation therapy is timely applied with a prompt diagnosis.
Acute Kidney Injury
;
Antibodies, Antiphospholipid
;
Antiphospholipid Syndrome
;
Humans
;
Kidney
;
Kidney Transplantation
;
Lupus Coagulation Inhibitor
;
Risk Factors
;
Transplantation, Homologous
;
Transplants
3.Columnar variant of papillary carcinoma in the thyroglossal duct cyst with progression to lung metastasis.
Yujung YUN ; Hye Jung PARK ; Young Ki LEE ; Yongin CHO ; Beoduel KANG ; Hyun Ju KIM ; Jung Hee LEE ; Moo Nyun JIN ; Dong Yeob SHIN
Yeungnam University Journal of Medicine 2014;31(2):103-108
Thyroglossal duct cyst (TGDC) carcinoma generally shows a favorable prognosis. If metastasis is present latently, it may not threaten the patient's life immediately. It has been shown, however, that larger than 1 cm papillary carcinoma (PC), level VI metastasis to the lymph node (LN), which is the nearest to the thyroid, independently predicts a worse prognosis. In the case presented herein, a 61-year-old female patient was diagnosed with an about 3 cm PC in the TGDC, particularly the columnar variant subtype, one of the aggressive variants. She had occult papillary thyroid microcarcinoma, but no LN metastasis. Even though she underwent the Sistrunk procedure and total thyroidectomy with central compartment neck dissection followed by high-dose radioactive iodine remnant ablation, however, the cancer cells spread to level IV neck LN, and finally to the lung. Therefore, when a patient is diagnosed with an aggressive histologic variant of PC in the TGDC, even without LN metastasis, the invasive surgical approach and close postoperative surveillance are necessary, with consideration of the risk of disease progression. Therefore, if it is possible to stratify the risk for patients, higher-risk patients can be offered a more invasive therapeutic approach.
Carcinoma, Papillary*
;
Disease Management
;
Disease Progression
;
Female
;
Humans
;
Iodine
;
Lung*
;
Lymph Nodes
;
Middle Aged
;
Neck
;
Neck Dissection
;
Neoplasm Metastasis*
;
Prognosis
;
Thyroglossal Cyst*
;
Thyroid Gland
;
Thyroidectomy
4.Pandemic Influenza (H1N1) and Mycobacterium tuberculosis Co-infection.
Yehyun PARK ; Bum Sik CHIN ; Sang Hoon HAN ; Yujung YUN ; Young Ju KIM ; Jun Yong CHOI ; Chang Oh KIM ; Young Goo SONG ; June Myung KIM
Tuberculosis and Respiratory Diseases 2014;76(2):84-87
We hereby observe four co-infection cases of pandemic influenza H1N1 and Mycobacterium tuberculosis with various clinical presentations. It may be prudent to consider M. tuberculosis co-infections when patients with pandemic influenza reveal unusual clinical features that do not improve despite appropriate treatments against the influenza, especially in Korea, in the endemic areas of M. tuberculosis.
Coinfection*
;
Humans
;
Influenza A Virus, H1N1 Subtype
;
Influenza, Human*
;
Korea
;
Mycobacterium tuberculosis*
;
Mycobacterium*
;
Pandemics*
;
Tuberculosis
5.Radiation Recall Dermatitis Induced by Gefitinib.
Beodeul KANG ; Ah Young LEEM ; Young Jae KIM ; Eudong HWANG ; Yujung YUN ; Sun Wook KIM ; Hyo Song KIM
The Ewha Medical Journal 2013;36(Suppl):S17-S21
Radiation recall dermatitis refers to an acute inflammatory reaction in a previously irradiated field triggered by the administration of certain drugs days to years after the exposure to radiation. Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor and is an effective treatment for patients with advanced stage of non small cell lung cancer (NSCLC). Here, we report a rare case of gefitinib induced radiation recall dermatitis. A 52-year-old woman with a metastatic NSCLC had received a palliative radiation therapy of 20 cGy on spine metastasis area (C6-T6). After 24 days of receiving radiation therapy, she had started to take gefitinib. Eight months after taking drug, pain, swelling and erythema of skin were occurred on previously irradiated field. These symptoms were resolved after the cessation of gefitinib for 6 days and the topical use of steroid.
Erythema
;
Female
;
Humans
;
Lung Neoplasms
;
Middle Aged
;
Neoplasm Metastasis
;
Protein-Tyrosine Kinases
;
Radiodermatitis*
;
Receptor, Epidermal Growth Factor
;
Skin
;
Small Cell Lung Carcinoma
;
Spine
6.Radiation Recall Dermatitis Induced by Gefitinib.
Beodeul KANG ; Ah Young LEEM ; Young Jae KIM ; Eudong HWANG ; Yujung YUN ; Sun Wook KIM ; Hyo Song KIM
The Ewha Medical Journal 2013;36(Suppl):S17-S21
Radiation recall dermatitis refers to an acute inflammatory reaction in a previously irradiated field triggered by the administration of certain drugs days to years after the exposure to radiation. Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor and is an effective treatment for patients with advanced stage of non small cell lung cancer (NSCLC). Here, we report a rare case of gefitinib induced radiation recall dermatitis. A 52-year-old woman with a metastatic NSCLC had received a palliative radiation therapy of 20 cGy on spine metastasis area (C6-T6). After 24 days of receiving radiation therapy, she had started to take gefitinib. Eight months after taking drug, pain, swelling and erythema of skin were occurred on previously irradiated field. These symptoms were resolved after the cessation of gefitinib for 6 days and the topical use of steroid.
Erythema
;
Female
;
Humans
;
Lung Neoplasms
;
Middle Aged
;
Neoplasm Metastasis
;
Protein-Tyrosine Kinases
;
Radiodermatitis*
;
Receptor, Epidermal Growth Factor
;
Skin
;
Small Cell Lung Carcinoma
;
Spine
7.Development of a Coronary Aneurysm at a Sirolimus-Eluting Stent-Implanted Lesion in a Patient With Churg-Strauss Syndrome.
Yujung CHO ; Hyunmin CHOE ; Bo Ram KANG ; Min Yong PARK ; Joon Hyung DOH ; Jae Jin KWAK ; Bo Young YOON ; June NAMGUNG ; Sung Yun LEE ; Gam HUR
Korean Circulation Journal 2011;41(9):559-562
A coronary aneurysm (CA) can occur in sirolimus-eluting stent (SES)-implanted coronary lesions. Although several possible mechanisms have been suggested, the precise pathogenesis of a CA in SES-implanted lesions is still unknown. We report a patient with Churg-Strauss syndrome who underwent successful percutaneous coronary intervention with SES and then experienced a CA in an SES-implanted coronary lesion. We describe the CA characteristics through the use of coronary angiography, coronary 64-multidetector computed tomography, and intravascular ultrasound and discuss the etiological factors for the CA in this patient.
Churg-Strauss Syndrome
;
Coronary Aneurysm
;
Coronary Angiography
;
Humans
;
Percutaneous Coronary Intervention
;
Stents
8.Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naive Korean Type 2 Diabetic Patients.
Young Ki LEE ; Sun Ok SONG ; Kwang Joon KIM ; Yongin CHO ; Younjeong CHOI ; Yujung YUN ; Byung Wan LEE ; Eun Seok KANG ; Bong Soo CHA ; Hyun Chul LEE
Diabetes & Metabolism Journal 2013;37(6):465-474
BACKGROUND: This study compared the glycemic effectiveness of three metformin-based dual therapies according to baseline hemoglobin A1c (HbA1c) to evaluate the appropriateness of the guideline enforced by the National Health Insurance Corporation of Korea for initial medication of type 2 diabetes (T2D). METHODS: This prospective observational study was conducted across 24 weeks for drug-naive Korean T2D patients with HbA1c greater than 7.5%. Subjects were first divided into three groups based on the agent combined with metformin (group 1, gliclazide-modified release or glimepiride; group 2, pioglitazone; group 3, sitagliptin). Subjects were also classified into three categories according to baseline HbA1c (category I, 7.5%< or =HbA1c<9.0%; category II, 9.0%< or =HbA1c<11.0%; category III, 11.0%< or =HbA1c). RESULTS: Among 116 subjects, 99 subjects completed the study, with 88 subjects maintaining the initial medication. While each of the metformin-based dual therapies showed a significant decrease in HbA1c (group 1, 8.9% to 6.4%; group 2, 9.0% to 6.6%; group 3, 9.3% to 6.3%; P<0.001 for each), there was no significant difference in the magnitude of HbA1c change among the groups. While the three HbA1c categories showed significantly different baseline HbA1c levels (8.2% vs. 9.9% vs. 11.9%; P<0.001), endpoint HbA1c was not different (6.4% vs. 6.6% vs. 6.0%; P=0.051). CONCLUSION: The three dual therapies using a combination of metformin and either sulfonylurea, pioglitazone, or sitagliptin showed similar glycemic effectiveness among drug-naive Korean T2D patients. In addition, these regimens were similarly effective across a wide range of baseline HbA1c levels.
Diabetes Mellitus, Type 2
;
Humans
;
Korea
;
Metformin
;
National Health Programs
;
Prospective Studies
;
Sitagliptin Phosphate
9.The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.
Eun Yeong CHOE ; Yongin CHO ; Younjeong CHOI ; Yujung YUN ; Hye Jin WANG ; Obin KWON ; Byung Wan LEE ; Chul Woo AHN ; Bong Soo CHA ; Hyun Chul LEE ; Eun Seok KANG
Diabetes & Metabolism Journal 2014;38(3):211-219
BACKGROUND: We evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus. METHODS: A total of 170 type 2 diabetes patients treated with sitagliptin or vildagliptin for more than 24 weeks were selected. The patients were separated into two groups, sitagliptin (100 mg once daily, n=93) and vildagliptin (50 mg twice daily, n=77). We compared the effect of each DPP-4 inhibitor on metabolic parameters, including the fasting plasma glucose (FPG), postprandial glucose (PPG), glycated hemoglobin (HbA1c), and glycated albumin (GA) levels, and lipid parameters at baseline and after 24 weeks of treatment. RESULTS: The HbA1c, FPG, and GA levels were similar between the two groups at baseline, but the sitagliptin group displayed a higher PPG level (P=0.03). After 24 weeks of treatment, all of the glucose-related parameters were significantly decreased in both groups (P=0.001). The levels of total cholesterol and triglycerides were only reduced in the vildagliptin group (P=0.001), although the sitagliptin group received a larger quantity of statins than the vildagliptin group (P=0.002).The mean change in the glucose- and lipid-related parameters after 24 weeks of treatment were not significantly different between the two groups (P=not significant). Neither sitagliptin nor vildagliptin treatment was associated with a reduction in the high sensitive C-reactive protein level (P=0.714). CONCLUSION: Vildagliptin and sitagliptin exert a similar effect on metabolic parameters, but vildagliptin exerts a more potent beneficial effect on lipid parameters.
Blood Glucose
;
C-Reactive Protein
;
Cholesterol
;
Diabetes Mellitus
;
Diabetes Mellitus, Type 2
;
Fasting
;
Glucose
;
Hemoglobin A, Glycosylated
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Triglycerides
;
Sitagliptin Phosphate